Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

the Company's filings with the Securities and Exchange Commission.

    APPENDIX
    1. Principal Risks and Uncertainties
    RISKS RELATED TO THE GROUP'S BUSINESS
    The Group's new products may not be a commercial success

Shire has launched a number of new products in the last four years, including key new products ELAPRASE, VYVANSE, LIALDA, FIRAZYR and FOSRENOL (Rest of World ('ROW')). The commercial success of these new products, as well as other new products that the Group may launch in the future, will depend on their approval and acceptance by physicians, patients and other key decision-makers, as well as the timing of the receipt of marketing approvals, the scope of marketing approvals as reflected in the product's label, the countries in which such approvals are obtained, the authorization of price and reimbursement in those countries where price and reimbursement is negotiated, and safety, efficacy, convenience and cost-effectiveness of the product as compared to competitive products.

The Group may not be able to grow revenues in its new products as quickly as anticipated if any or all of the following occur:

    - if competitive products are genericised and the impact on the market
      negatively affects the prescribing of branded treatments for the
      indications that the Group's new products treat;

    - if there are unanticipated adverse events experienced with the Group's
      new products not seen in clinical trials that impact the physician's
      willingness to prescribe the Group's new products;

    - if issues arise from clinical trials being conducted for post marketing
      purposes or for registration in another country or regulatory agencies
      in one country act in a way that causes concern for prescribers or
      patients in another country;

    - if patients, payors or physicians favor older treatments over newer
      treatments;

    -
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... 2015  SeraCare Life Sciences, a leading partner ... that it has signed a Cooperative Research and ... (NCI), part of the National Institutes of Health, ... cancer assays.  The CRADA will investigate the development ... DNA biosynthetics spiked into a genomic DNA background ...
(Date:6/26/2015)... VANCOUVER , June 26, 2015 /PRNewswire/ - iCo ... ICOTF), today announced that all nominees listed in ... as directors at its 2015 Annual Meeting of ... a vote by ballot, the following 5 nominees ... iCo Therapeutics to serve until the Company,s next ...
(Date:6/26/2015)... 2015  A San Francisco company, Pembient, recently announced ... rhino horn: beer in China ... In response to the emerging industry, two leading rhino ... of synthetic rhino horn.  The ... Rhino International (SRI) released a joint statement ...
(Date:6/26/2015)... , ... June 26, 2015 , ... ... announced that its SimplePrep™ technologies have been integrated into a sample prep module ... Station (ISS) as a part of the NASA’s WetLab-2 Project. , On June ...
Breaking Biology Technology:SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 , , ... , , , Microorganism , ... Cell type , Bacteria, gram negative, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , Multiporator / Electroporator 2510 , , , , , , ... Protocol , Protocol No. 4308 915.502 12/2001 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
Cached Biology Technology:Borrelia burgdorferi 2Bifidobacterium animalis 2Agrobacterium tumefaciens 2
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... the Southern Ocean, large quantities of surface-drifting plankton algae are ... surface waters, which can affect the global carbon dioxide cycle. ... which has just drawn to a close in Cape Town ... Wegener Institute, part of the Helmholtz Association. On February 5, ...
... Rochet, a research scientist at IFREMER (The French Research ... the prestigious Pew Fellowship in Marine Conservation to determine ... to the delicately balanced marine ecosystem. She will use ... use of that technique, and to further improve its ...
... YORK CITY - Dr. Ussif Rashid Sumaila, an Associate ... in Vancouver, Canada, is among five ocean experts to ... Conservation, which supports critical marine conservation projects around the ... the financial factors contributing to unsustainable commercial fishing and ...
Cached Biology News:Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 2Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 3Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 42008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 32008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 42008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 22008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 32008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 4
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: